keyword
Keywords overall survival lapatinib bre...

overall survival lapatinib breast cancer

https://read.qxmd.com/read/36417083/dual-neoadjuvant-blockade-plus-chemotherapy-versus-monotherapy-for-the-treatment-of-women-with-non-metastatic-her2-positive-breast-cancer-a-systematic-review-and-meta-analysis
#21
REVIEW
Juan Carlos Vazquez, Silvia Antolin, Manuel Ruiz-Borrego, Sonia Servitja, Emilio Alba, Agusti Barnadas, Ana Lluch, Miguel Martin, Alvaro Rodriguez-Lescure, Ivan Sola, Xavier Bonfill, Gerard Urrutia, Pedro Sanchez-Rovira
BACKGROUND: We aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. METHODS: We carried out a systematic review updated until July 2022. The outcomes included pathological complete response (pCR), clinical response, event-free survival, and overall survival. RESULTS: We identified eleven randomized clinical trials (2836 patients). When comparing paclitaxel plus dual treatment versus paclitaxel plus trastuzumab or lapatinib, dual treatment was associated with a higher probability of achieving a pathological complete response (OR 2...
November 22, 2022: Clinical & Translational Oncology
https://read.qxmd.com/read/36358602/the-prognostic-and-therapeutic-implications-of-the-chemoresistance-gene-birc5-in-triple-negative-breast-cancer
#22
JOURNAL ARTICLE
Getinet M Adinew, Samia Messeha, Equar Taka, Karam F A Soliman
Chemoresistance affects TNBC patient treatment responses. Therefore, identifying the chemoresistant gene provides a new approach to understanding chemoresistance in TNBC. BIRC5 was examined in the current study as a tool for predicting the prognosis of TNBC patients and assisting in developing alternative therapies using online database tools. According to the examined studies, BIRC5 was highly expressed in 45 to 90% of TNBC patients. BIRC5 is not only abundantly expressed but also contributes to resistance to chemotherapy, anti-HER2 therapy, and radiotherapy...
October 22, 2022: Cancers
https://read.qxmd.com/read/36277284/characterization-of-glucose-metabolism-in-breast-cancer-to-guide-clinical-therapy
#23
JOURNAL ARTICLE
Yingying Mei, Lantao Zhao, Man Jiang, Fangfang Yang, Xiaochun Zhang, Yizhen Jia, Na Zhou
Background: Breast cancer (BRCA) ranks as a leading cause of cancer death in women worldwide. Glucose metabolism is a noticeable characteristic of the occurrence of malignant tumors. In this study, we aimed to construct a novel glycometabolism-related gene (GRG) signature to predict overall survival (OS), immune infiltration and therapeutic response in BRCA patients. Materials and methods: The mRNA sequencing and corresponding clinical data of BRCA patients were obtained from public cohorts...
2022: Frontiers in Surgery
https://read.qxmd.com/read/36230471/prognostic-value-of-the-serum-her2-extracellular-domain-level-in-breast-cancer-a-systematic-review-and-meta-analysis
#24
REVIEW
Yun Wu, Lixi Li, Di Zhang, Fei Ma
An elevated serum HER2 extracellular domain is associated with poor prognosis in breast cancer, but the relationship between sHER2 and the efficacy of different modalities remains controversial. Herein, we aimed to evaluate the prognostic value of serum HER2 extracellular domain (sHER2 ECD) in breast cancer and to identify its correlation with the efficacy of different treatment regimens. A systematic search of the PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases was conducted to identify studies exploring the association between HER2 ECD level and clinical outcomes among patients with breast cancer...
September 20, 2022: Cancers
https://read.qxmd.com/read/36203428/identification-of-novel-cuproptosis-related-lncrna-signatures-to-predict-the-prognosis-and-immune-microenvironment-of-breast-cancer-patients
#25
JOURNAL ARTICLE
Zi-Rong Jiang, Lin-Hui Yang, Liang-Zi Jin, Li-Mu Yi, Ping-Ping Bing, Jun Zhou, Jia-Sheng Yang
Background: Cuproptosis is a new modality of cell death regulation that is currently considered as a new cancer treatment strategy. Nevertheless, the prognostic predictive value of cuproptosis-related lncRNAs in breast cancer (BC) remains unknown. Using cuproptosis-related lncRNAs, this study aims to predict the immune microenvironment and prognosis of BC patients. and develop new therapeutic strategies that target the disease. Methods: The Cancer Genome Atlas (TCGA) database provided the RNA-seq data along with the corresponding clinical and prognostic information...
2022: Frontiers in Oncology
https://read.qxmd.com/read/36199295/efficacy-and-safety-of-pyrotinib-in-human-epidermal-growth-factor-receptor-2-positive-advanced-breast-cancer-a-multicenter-retrospective-real-world-study
#26
JOURNAL ARTICLE
Xiaoling Zhang, Zhaohui Li, Linlin Han, Zheng Lv, Yuee Teng, Xiujie Cui, Caiyun Zhou, Hongwei Wu, Wei Fang, Lingzhi Xu, Shanshan Zhao, Chen Song, Yuanyuan Zheng, Tianqi Gao, Man Li
Purpose: Pyrotinib, a novel human epidermal growth factor receptor 2 (HER2)-targeted tyrosine kinase inhibitor (TKI), has led to remarkable survival outcomes in HER2-positive advanced breast cancer (ABC) in clinical trials and was approved for second-line standards of treatment for HER2+ ABC in China. However, the clinical trials could not fully reflect reality of clinical practice, and predictive factors were still lacking. This study aimed to assess the actual efficacy and safety of pyrotinib in HER2+ ABC in real-world setting...
2022: OncoTargets and Therapy
https://read.qxmd.com/read/36130155/clinical-profile-and-outcome-of-patients-with-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-with-brain-metastases-real-world-experience
#27
JOURNAL ARTICLE
Prabhat Bhargava, Narmadha Rathnasamy, Ramnath Shenoy, Seema Gulia, Jyoti Bajpai, Jaya Ghosh, Sushmita Rath, Ashwini Budrukkar, Tanuja Shet, Asawari Patil, Sangeeta Desai, Nita Nair, Shalaka Joshi, Palak Popat, Tabassum Wadasadawala, Rima Pathak, Rajiv Sarin, Sadhana Kannan, Rajendra Badwe, Sudeep Gupta
PURPOSE: There are sparse data in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases from real-world settings, especially where access to newer targeted therapies is limited. METHODS: This was a single institution, retrospective cohort study of patients with HER2-positive breast cancer diagnosed between January 2013 and December 2017 to have brain metastases and treated with any HER2-targeted therapy. The main objectives were to estimate progression-free survival (PFS) and overall survival (OS) from the time of brain metastases...
September 2022: JCO global oncology
https://read.qxmd.com/read/36050448/outcomes-of-patients-with-small-and-node-negative-her2-positive-early-breast-cancer-treated-with-adjuvant-chemotherapy-and-anti-her2-therapy-a-sub-analysis-of-the-altto-study
#28
JOURNAL ARTICLE
Guilherme Nader-Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen I Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
BACKGROUND: Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the long-term outcomes of patients with small node-negative tumours. METHODS: The ALTTO trial randomised 8381 patients with early HER2-positive BC treated with adjuvant chemotherapy (anthracycline/taxane- or taxane/carboplatin-based), to trastuzumab (T), lapatinib (L), their sequence (T → L) or their combination (L + T)...
November 2022: British Journal of Cancer
https://read.qxmd.com/read/35957895/effect-of-pyroptosis-related-genes-on-the-prognosis-of-breast-cancer
#29
JOURNAL ARTICLE
Ying Zhou, Jianfeng Zheng, Mengru Bai, Yuzhen Gao, Nengming Lin
Backgrounds: Pyroptosis, a newly pattern of specific programmed cell death, has been reported to participate in several cancers. However, the value of pyroptosis in breast cancer (BRCA) is still not clear. Methods: Herein, we analyzed the data of BRCA from both The Cancer Genome Atlas (TCGA) and GSEA MSigDB database. Based on the obtained pyroptosis-related genes (PRGs), we searched the interactions by STRING. After that, we performed clustering analysis by ConsensusClusterPlus...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35859079/predict-underestimates-survival-of-patients-with-her2-positive-early-stage-breast-cancer
#30
JOURNAL ARTICLE
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé, Christian Maurer, Sarra El-Abed, Yingbo Wang, Malou Vicente, Saranya Chumsri, Judith Bliss, Judith Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine Piccart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini
The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic performance using data extracted from ALTTO, a phase III trial evaluating adjuvant lapatinib ± trastuzumab vs. trastuzumab alone in patients with HER2-positive EBC. Our analysis included 2794 patients. After a median follow-up of 6.0 years (IQR, 5.8-6.7), 182 deaths were observed...
July 20, 2022: NPJ Breast Cancer
https://read.qxmd.com/read/35844533/determining-the-optimal-neo-adjuvant-regimen-for-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-regarding-survival-outcome-a-network-meta-analysis
#31
Yu-Wen Cai, Zhi-Ming Shao, Ke-Da Yu
Background: The optimal (neo)adjuvant regimen for human epidermal growth factor receptor-2 (HER2)-positive breast cancer regarding survival outcomes remains unclear. Methods: We searched Web of Science, PubMed, and the Cochrane Central Register of Controlled Trials systematically to find out randomized controlled studies, up to January 2022, that compared different anti-HER2 regimens in the (neo)adjuvant setting. The primary endpoint was disease-free survival (DFS)...
2022: Frontiers in Immunology
https://read.qxmd.com/read/35653982/efficacy-of-tyrosine-kinase-inhibitors-for-the-treatment-of-patients-with-her2-positive-breast-cancer-with-brain-metastases-a-systematic-review-and-meta-analysis
#32
REVIEW
G Nader-Marta, D Martins-Branco, E Agostinetto, M Bruzzone, M Ceppi, L Danielli, M Lambertini, N Kotecki, A Awada, E de Azambuja
BACKGROUND: Brain metastases (BMs) are frequent events in patients with HER2-positive metastatic breast cancer (MBC) and are associated with poor prognosis. Small-molecule anti-HER2 tyrosine kinase inhibitors (TKIs) are promising agents for the treatment of BM. In this study, we assess the clinical outcomes of patients with HER2-positive MBC and BM treated with TKI-containing regimens compared with those treated with non-TKI-containing regimens. MATERIALS AND METHODS: PubMed, Embase, Cochrane Library, and conference proceedings (ASCO, SABCS, ESMO, and ESMO Breast) were searched up to June 2021...
May 30, 2022: ESMO Open
https://read.qxmd.com/read/35621719/real-world-outcomes-among-patients-with-her2-metastatic-breast-cancer-with-brain-metastases
#33
JOURNAL ARTICLE
Kendra DeBusk, Chiemeka Ike, Nicolas Lindegger, Naomi Schwartz, Andy Surinach, Yutong Liu, Andres Forero-Torres
BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the high unmet need for patients with HER2+ MBC and BMs, real-world data on treatment patterns and outcomes for these patients are limited. OBJECTIVE: To compare treatment patterns and overall survival (OS) among patients with HER2+ MBC with and without BMs in the United States. METHODS: This was a real-world retrospective cohort study in which adults diagnosed with HER2+ MBC between January 1, 2016, and May 31, 2019, were identified in the Flatiron Health electronic health records database...
June 2022: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/35490579/patient-reported-outcomes-predict-survival-and-adverse-events-following-anticancer-treatment-initiation-in-advanced-her2-positive-breast-cancer
#34
JOURNAL ARTICLE
N D Modi, N O Danell, R N A Perry, A Y Abuhelwa, A Rathod, S Badaoui, R A McKinnon, M Haseloff, A Shahnam, S M Swain, M Welslau, M J Sorich, A M Hopkins
BACKGROUND: The prognostic value of patient-reported outcomes (PROs) has been minimally explored in advanced breast cancer (BC), and their comparative prognostic performance against Eastern Cooperative Oncology Group performance status (ECOG PS) is largely unknown. PATIENTS AND METHODS: This study pooled individual participant data from clinical trials CLEOPATRA, EMILIA, and MARIANNE. Pre-treatment PRO associations with overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events were evaluated via Cox proportional hazards regression...
April 28, 2022: ESMO Open
https://read.qxmd.com/read/35448925/-a-real-world-study-on-the-relationship-between-drug-resistance-of-targeted-therapy-and-prognosis-of-her-2-positive-advanced-breast-cancer
#35
JOURNAL ARTICLE
Z J Wang, Y Q Han, Q Li, H N Mo, Y Q Li, X W Guan, Y M Chen, S Y Lin, B H Xu, Q Li, P Zhang, F Ma
Objective: To explore the effect of primary and acquired resistance to anti-human epidermal growth factor receptor 2 (HER-2) on the overall survival of patients with HER-2 positive advanced breast cancer. Methods: The clinical characteristics of HER-2 positive patients with advanced breast cancer admitted to Cancer Hospital of Chinese Academy of Medical Sciences from January 1998 to December 2018 were collected, and their neoadjuvant/adjuvant and advanced three-line chemotherapy were summarized. Among them, targeted drugs for HER-2 included trastuzumab, pertuzumab, T-DM1, RC48-ADC, lapatinib, pyrotinib, allitinib, sipatinib, seratinib...
April 23, 2022: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/35356262/treatment-with-pyrotinib-based-therapy-in-lapatinib-resistant-her2-positive-metastatic-breast-cancer-a-multicenter-real-world-study
#36
JOURNAL ARTICLE
Yijia Hua, Wei Li, Nan Jin, Dongyan Cai, Jie Sun, Chunxiao Sun, Fan Yang, Xinyu Wu, Xiang Huang, Biyun Wang, Yongmei Yin
Background: Tyrosine kinase inhibitors (TKIs) are effective for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, therapies subsequent to TKI progression remain controversial, and effective treatments for TKI resistance are urgently needed. We evaluate the practice of exchange of TKIs, which involves treatment with a different TKI following prior TKI failure. Specifically, this study investigated the efficacy of pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer (NCT04899128)...
2022: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/34844517/the-efficacy-of-lapatinib-in-patients-with-metastatic-her2-positive-breast-cancer-who-received-prior-therapy-with-monoclonal-antibodies-and-antibody-drug-conjugate-a-single-institutional-experience
#37
JOURNAL ARTICLE
Ivana Kolarov Bjelobrk, Jelena Radic, Jasna Trifunovic, Jasna Pesic, Vladimir Vidovic, Bojana Vranjkovic, Nemanja Petrovic, Bojana Andrejic Visnjic
The choice of the anti-HER2 agent depends on country-specific availability, the specific, previously administered anti-HER2 therapy and the relapse-free interval, although there is not much published data on the use of lapatinib after progression on pertuzumab and/or T-DM1. The aim of this research is to determine efficacy of lapatinib in this setting. This research included 111 patients with metastatic HER2 positive breast cancer who received lapatinib with capecitabine at The Oncology Institute of Vojvodina...
November 30, 2021: Journal of Chemotherapy
https://read.qxmd.com/read/34701797/outcomes-of-patients-with-her2-positive-breast-cancer-metastatic-to-brain-treated-with-her2-targeted-systemic-therapy-and-stereotactic-radiosurgery
#38
JOURNAL ARTICLE
J W Shumway, M Torras, K Reeder Hayes, T Jolly, E C Dees, E M Ray, L A Carey, C Shen
PURPOSE/OBJECTIVE(S): For patients with HER2-positive breast cancer metastatic to brain, HER2-directed systemic therapies are increasingly used with stereotactic radiosurgery (SRS), with a goal to avoid or delay whole brain radiotherapy. These include monoclonal antibodies such as trastuzumab (Herceptin, H) and pertuzumab (Perjeta, P), antibody-drug conjugates such as ado-trastuzumab emtansine (T-DM1), and tyrosine kinase inhibitors such as lapatinib. Limited data exist regarding appropriate timing with SRS and outcomes of this treatment regimen for HER2-positive breast cancer metastatic to the brain...
November 1, 2021: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/34654856/human-induced-pluripotent-stem-cell-derived-platelets-loaded-with-lapatinib-effectively-target-her2-breast-cancer-metastasis-to-the-brain
#39
JOURNAL ARTICLE
Arunoday Bhan, Khairul Ansari, Mike Y Chen, Rahul Jandial
Prognosis of patients with HER2+ breast-to-brain-metastasis (BBM) is dismal even after current standard-of-care treatments, including surgical resection, whole-brain radiation, and systemic chemotherapy. Radiation and systemic chemotherapies can also induce cytotoxicity, leading to significant side effects. Studies indicate that donor-derived platelets can serve as immune-compatible drug carriers that interact with and deliver drugs to cancer cells with fewer side effects, making them a promising therapeutic option with enhanced antitumor activity...
October 15, 2021: Scientific Reports
https://read.qxmd.com/read/34553296/analysis-of-the-pan-asian-subgroup-of-patients-in-the-nala-trial-a-randomized-phase-iii-nala-trial-comparing-neratinib-capecitabine-n-c-vs-lapatinib-capecitabine-l-c-in-patients-with-her2-metastatic-breast-cancer-mbc-previously-treated-with-two-or-more-her2
#40
JOURNAL ARTICLE
Ming Shen Dai, Yin Hsun Feng, Shang Wen Chen, Norikazu Masuda, Thomas Yau, Shou Tung Chen, Yen Shen Lu, Yoon Sim Yap, Peter C S Ang, Sung Chao Chu, Ava Kwong, Keun Seok Lee, Samuel Ow, Sung Bae Kim, Johnson Lin, Hyun Cheol Chung, Roger Ngan, Victor C Kok, Kun Ming Rau, Takafumi Sangai, Ting Ying Ng, Ling Ming Tseng, Richard Bryce, Judith Bebchuk, Mei Chieh Chen, Ming Feng Hou
PURPOSE: Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed the efficacy and safety of neratinib+capecitabine (N+C) against lapatinib+capecitabine (L+C) in HER2+ metastatic breast cancer (mBC) patients who had received ≥ 2 HER2-directed regimens. Descriptive analysis results of the Asian subgroup in the NALA study are reported herein...
September 23, 2021: Breast Cancer Research and Treatment
keyword
keyword
107440
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.